Omnicom Retains Bristol Myers Squibb’s US Media Account, Expands HCP Mandate

Published on: November 20, 2026

Omnicom Media has retained the US media account of pharmaceutical company Bristol Myers Squibb (BMS) following a competitive agency review. The holding company has also expanded its responsibilities to include additional healthcare professional (HCP) media activities, with the updated mandate expected to begin in 2027, according to global reports.

The account retention marks a significant development for Omnicom following its acquisition of Interpublic Group (IPG). BMS’s US media business was previously managed by IPG Mediabrands, while WPP-owned CMI Media Group is understood to have overseen the HCP media assignment.

BMS has previously reviewed its media agency arrangements through competitive pitches. In 2023, IPG Mediabrands won the company’s US media account from Havas. At the time, reports citing a request for information issued during the review estimated BMS’s media budget at approximately $430 million. This figure reflects the 2023 account and should not be taken as the value of the latest mandate.

The latest win adds to Omnicom’s growing presence in pharmaceutical media. Earlier this year, Novo Nordisk appointed Omnicom to handle its US media buying business, transferring the account from WPP. Reports at the time placed the pharmaceutical company’s annual media expenditure at more than $600 million.

The BMS decision combines the retention of a client relationship inherited through the IPG acquisition with an expanded role in specialist healthcare media. It also highlights the broader realignment of client accounts among global advertising holding companies following the Omnicom-IPG merger.

Read more: Plaza Premium Group appoints G Squared to lead social media

Author Profile

About News Bureau

View all posts by News Bureau